SUNDAY, 1 NOVEMBER 2026

EDITORIAL REVIEW PROOF

GRAYMEDY

JOURNAL



THE IMMUNE FRONTIER

New ways to fight cancer, protect the gut and understand how we age.

THREE DEEP READS. ONE QUESTION: WHAT DOES THE EVIDENCE SHOW?

02

Cancer, more precisely

A selective T-cell stimulus

04

Beyond gluten avoidance

What a phase 2 signal means

06

The immune age question

Maps, mechanisms and proof

08 / Doctor Spotlight **09 / Product Spotlight**


Evidence & photo credits 10

Cover: National Cancer Institute / Unsplash

PHASE 1/2 / PEER-REVIEWED

A more precise push against cancer

An experimental antibody is finding signs of activity in cancers that resisted immunotherapy. The signal matters. So does the small denominator.



A technician examines cells at the NCI Cancer Genomics Research Laboratory. Context photograph; not the START-001 trial. Credit: National Cancer Institute / Unsplash.

When the next option is a question

For someone whose cancer has stopped responding to treatment, an early trial can carry an extraordinary weight of hope. The distinction between an early response and lasting benefit matters deeply in that setting. A drug can deserve attention before researchers know whether it will help patients live longer. October brought one such signal: invikafusp alfa, also called invika, an experimental antibody being tested against difficult solid tumours. It is a reason to investigate, rather than a promise to the next person who needs treatment.

What changed this month

A Nature Medicine paper published on 23 October reports the phase 1/2 START-001 study. Invika selectively stimulates two T-cell families, labelled V-beta 6 and V-beta 10. The study included 34 people in dose escalation and 18 in the initial phase 2 group. Its early objectives included evaluating safety and choosing a dose for further testing. The analysis used a March 2025 data cutoff: publication month and observation period are different dates. [1]

Read the denominator

Across the two optimal biological dose groups, four of 27 participants had an objective tumour response, a rate of 14.8%. NIH separately reports disease control in 16 of those 27 people, or 59.3%. These are different outcomes. A tumour that remains stable contributes to disease control; it has not necessarily shrunk. Neither percentage establishes a survival advantage. Most participants had cancers resistant to immune checkpoint blockade, making the observed activity scientifically interesting. [1,2]

Why the approach is interesting

Cancer immunotherapy asks the immune system to recognise or attack a malignancy. NCI describes several approaches, including checkpoint inhibitors, antibodies and cellular treatments. Invika is an antibody intended to activate selected T cells; it is not a personalised CAR-T cell infusion. The aim is useful activity where earlier treatments failed, with unwanted inflammation kept manageable. Further clinical testing must establish whether that selective approach produces a favourable balance of benefit and harm. [1,3]

THE EVIDENCE, IN CONTEXT

Four responses are a signal. They are not a survival result.

The safety balance

Safety is central to that question. The paper identifies cytokine release syndrome as the most common treatment-related adverse event, mostly grade 1 or 2, and reports two reversible dose-limiting toxicities. A favourable early safety description does not mean treatment is risk-free. NCI notes that immunotherapy can inflame healthy tissues and that adverse effects vary by treatment and person. Symptoms can arise during or after therapy, which makes follow-up part of the evidence rather than an administrative detail. [1,4]

What would make the signal stronger?

A small early study is built to answer a limited set of questions. Later work needs to show which cancer types benefit, how long responses last and whether the balance of benefit and harm remains favourable in more patients. Comparisons are especially important: without a suitable control group, a response rate alone cannot establish superiority over another option. NCI explains that later trial phases generally expand the population and compare a new approach with established care. That progression is a method for reducing uncertainty. [5]

Life between treatments

Treatment occupies more than the hours spent receiving a medicine. Travel, recovery and repeated appointments can shape the rest of the week for a person living with advanced cancer. Family life, work and the energy available for ordinary activities matter alongside tumour measurements. A lasting response may be valuable, but its practical meaning also depends on symptoms and treatment burden. Response duration, adverse effects and quality of life give a fuller picture of benefit than tumour shrinkage alone.

Why comparisons need care

Response rates from different trials cannot be treated as a league table. Cancer type, previous treatment, eligibility and follow-up all influence the population being measured. The START-001 percentages describe one dose subgroup; they do not establish superiority over another treatment. Expansion of selected immune cells supports the proposed mechanism without explaining why each individual responded. Larger comparative studies could clarify how consistently that biological activity translates into clinical benefit.

The verdict

Invika's early activity supports continued investigation. NIH says the trial remains open and describes Fast Track designations, which facilitate development without constituting approval or proof of survival benefit. Participation requires assessment of eligibility, alternatives, monitoring and potential harms with a treating team. Whether the medicine can provide durable benefit, and where it might fit into cancer care, remain unresolved. [2,5]

READ THE SAME 27 PEOPLE TWO WAYS



Objective response: 4 of 27



Disease control: 16 of 27

Different outcomes; not a treatment comparison. No survival benefit established. Sources [1,2].

Research is a sequence

A dose-finding signal earns further testing. Later comparative evidence must establish where a treatment belongs. [5]

References 1-5 on page 10.

PHASE 2 / COMPANY TOPLINE

Beyond the gluten-free plate

A phase 2 coeliac disease announcement points to intestinal protection. A future medicine must also prove that it makes daily life better.



Conventional bread illustrates a source of gluten. This is not a gluten-free product recommendation. Credit: Mae Mu / Unsplash.

The burden behind the label

A meal can be a calculation: the ingredients, the preparation surface, the shared serving spoon. For people managing coeliac disease, avoiding gluten is a medical necessity that reaches into ordinary social life. That is the context in which a potential medicine should be judged. A laboratory or biopsy result matters, but so does whether a treatment could eventually make an accidental exposure less consequential. October's FB102 news brings that possibility closer to a serious test without establishing that it has been achieved.

The October result

On 8 October, argenx announced that its investigational anti-CD122 antibody, FB102, met the primary endpoint in a phase 2 trial. The study enrolled 126 adults and compared two intravenous dose levels with placebo during a controlled eight-week gluten challenge. The endpoint assessed change in the ratio of villus height to crypt depth at day 78, a measure of intestinal architecture. The company reported p=0.0176 and plans phase 3 development. Detailed results were still to be presented. [6]

The size of the benefit matters

A p-value does not measure how much a treatment helps. The absolute difference between groups, the uncertainty around that estimate and the number of people who stop treatment all affect the clinical picture. Tissue protection, symptom relief and durable benefit are separate outcomes. A statistically significant biopsy result can support further development while leaving its everyday importance uncertain. Detailed efficacy and safety results are needed to establish how much protection FB102 provides, how consistently it works and whether its benefits justify the risks and inconvenience of treatment.

The care people need today

NIDDK describes a gluten-free diet as the central treatment for coeliac disease. Gluten triggers an immune reaction that damages the small intestine. Specialist dietetic support can help people read labels, plan meals and maintain nutritional balance. Follow-up may include blood tests and, in some cases, further biopsies to assess healing. Continuing symptoms deserve investigation rather than an assumption that the diet has simply failed; exposure and other conditions can contribute. [7]

THE EVIDENCE, IN CONTEXT

A future medicine must improve more than a biopsy slide.

Protection is a different ambition

FB102 is designed to interfere with CD122-related immune signalling. The sponsor reports no new safety signals, but that statement cannot replace a detailed safety table. A controlled gluten challenge is also a specific experimental setting. It cannot establish that a medicine permits unrestricted eating, works equally well in children or protects people indefinitely. The useful near-term question is narrower: does a larger, well-conducted trial reproduce meaningful protection with an acceptable burden of treatment? [6]

What happens outside a trial

The NHS highlights cross-contamination when gluten-free food shares equipment or preparation space with foods containing gluten. Its guidance also makes clear that symptoms and intestinal healing can proceed on different timescales. A future treatment would need to address those practical realities alongside the underlying immune reaction. A clinically useful programme should define whether it is intended to supplement avoidance, protect against accidental exposure or address another unmet need. Each purpose implies a different standard of evidence. [8]

The nutritional picture still matters

An evidence-based nutrition guideline published in 2023 supports lifelong gluten avoidance and routine nutritional assessment for people with coeliac disease. It does not support routine micronutrient supplementation without a deficiency. Nutritional support therefore depends on the individual's needs and test results. Any future drug would need to fit within this broader care pathway, with clear advice about diet, monitoring and the symptoms that warrant further assessment. [9]

Treatment within ordinary life

A treatment can offer protection while adding demands of its own. Repeated infusions may require travel, time away from work and arrangements for family care. The balance could differ for someone troubled mainly by accidental exposure and someone with persistent symptoms or nutritional problems. Fewer symptoms, better intestinal health and a manageable schedule are distinct goals. A medicine would need a defined role within the care plan, including which dietary precautions remain necessary and when symptoms or adverse effects require review.

The next clinical milestone

A confirmatory programme will need to establish both the magnitude of protection and the detailed safety profile. Outcomes beyond intestinal architecture include symptoms, nutritional health and the burden of receiving treatment. Affordability and access would shape the usefulness of any eventual medicine alongside its biological effect. None of those practical benefits follows automatically from a successful primary endpoint. The phase 2 announcement supports further research, but it does not change current dietary care. A gluten-free diet remains essential, and a controlled trial challenge is not a reason to attempt gluten exposure independently. [6-9]



NIH laboratory materials; not FB102. NCI / Unsplash.

References 6-9 on page 10.

WHAT THE RELEASE LEAVES OPEN

- Magnitude of benefit
- Durability of protection
- Detailed adverse-event rates
- Impact on ordinary daily life

OBSERVATIONAL / EARLY TRANSLATION

Can immunity age differently?

October brought a map of immune ageing and a new industry evaluation of a rejuvenation platform. Prediction and treatment remain separate scientific tasks.



An outdoor walk offers a human context for healthy ageing. Illustrative stock photograph; the people shown are not study participants. Credit: Mobio Marketing / Unsplash.

Start with the right ambition

The promise of ageing research is more time lived well. Immune resilience matters because older people may face several health challenges at once, while independence depends on more than a laboratory measurement. October brought a map of immune-cell patterns associated with later health and a programme preparing to test an intervention for cellular dysfunction. These developments highlight the distance between detecting a biological pattern and demonstrating that changing it improves lives.

A map, not yet a routine test

On 13 October, King's College London described research published in Immunity that analysed about 12.4 million immune cells from 2,609 mainly healthy adults across eight cohorts. The work linked different balances of granzyme K and granzyme B immune-cell populations to different ageing trajectories. A granzyme B-dominant pattern was associated with greater later disease and mortality risk. These are population associations; they do not make an individual's future inevitable or show that altering the ratio changes health. [10]

Why measurement matters

Current profiling requires complex, costly technology. The researchers hope the findings could support a simpler blood test. Clinical use would require validation in new populations, consistent performance and information that adds to routine assessment. An unusual immune profile might identify an association without establishing its cause or revealing an effective treatment. Prediction and clinical usefulness are different standards: a test needs to support a decision that can improve care. [10]

A separate attempt to intervene

UCL reported on 8 October that an unnamed pharmaceutical company would independently evaluate its DoS immune-rejuvenation platform. The programme, associated with Alessio Lanna and SenTcell Life, is preparing for first-in-human evaluation. UCL describes planned early attention to safety and biological activity in adults with immune dysfunction. The collaboration is a development milestone and a sign of commercial interest. It is not a clinical result, and the October announcement does not supply evidence of improved human health or longer life. [11]

THE EVIDENCE, IN CONTEXT

A younger-looking immune profile is not yet proof of a healthier life.

What came before

A June UCL announcement described plans for an injectable approach intended to restore features of worn-out T cells, with an initial phase 1 focus. Separately, a 2024 preprint reported experiments with disruptors of sestrin-MAPK interactions, including immune effects in old mice. That preprint is a record of early experimental work, not peer-reviewed clinical evidence. The experiments support a biological rationale for further testing. They do not establish that the planned treatment improves health in humans. [12,13]

From cellular change to clinical benefit

An intervention can change the behaviour of immune cells without producing a meaningful improvement in health. Biological activity may show that a therapy reaches its target; clinical benefit requires evidence that the change helps the person receiving it. Reliable measurement, reproducible effects and an acceptable balance of benefits and harms are all necessary. For immune-ageing treatments, durability is especially important: a temporary shift in a laboratory marker would have a different clinical meaning from a sustained reduction in illness or a lasting improvement in everyday function.

What human studies must establish

Early human studies need to define a suitable dose, characterise unwanted effects and establish whether the intended biological changes occur. Participant selection and follow-up influence what the results can establish. A study in adults with a particular immune dysfunction may not apply to healthy older people or to someone with a different chronic disease. Later trials must connect biological effects with outcomes such as illness, functional ability or quality of life. Early activity supports further investigation rather than widespread treatment. [5] A future diagnostic test faces a related challenge. An association discovered in one population needs to be reproduced in another, and a useful prediction must inform a decision that can improve care. If a treatment changes an immune marker without changing health outcomes, that difference is clinically important. The strongest evidence would show that altering a cellular process safely produces a benefit people can experience and sustain.

Two paths towards healthier ageing

The mapping study and the intervention programme approach immune ageing from different directions. One identifies patterns associated with future health; the other aims to alter cellular dysfunction. Their findings do not yet establish a combined clinical strategy. A successful treatment would need transparent human evidence showing meaningful benefits, acceptable harms and effects that endure. Commercial interest can help move a programme forward, but it cannot answer those clinical questions. Immune rejuvenation remains an investigational approach, with an important boundary between a promising mechanism and a treatment demonstrated to improve lives. [10-13]



Electron microscopy. NCI / Unsplash.

References 5, 10-13 on page 10.

TWO SEPARATE RESEARCH TASKS

MEASURE Identify patterns associated with later health.

INTERVENE Test whether changing dysfunction safely improves outcomes.

One does not establish the success of the other.

Dr. Harold Varmus

Connecting cancer discovery with access to knowledge.

GRAYMEDY EDITORIAL / PUBLISHED 29 OCTOBER 2026




Photo: Matthew Septimus / NCI via Wikimedia Commons, 2009.

From normal genes to cancer

Varmus and J. Michael Bishop shared the 1989 Nobel Prize in Physiology or Medicine for discovering the cellular origin of retroviral oncogenes. The Nobel account describes their 1976 conclusion that a cancer-causing gene carried by a virus had come from normal cells. The finding helped redirect attention towards cellular growth-control machinery and how it can go wrong. It opened a field of questions rather than providing an immediate treatment for every cancer. [15]

Leading research institutions

NIH records his directorship from 1993 to 1999. He later led Memorial Sloan Kettering Cancer Center and directed NCI from 2010 to 2015. These are historical appointments. They show how a physician's contribution can include supporting the conditions in which other researchers work, alongside conducting experiments. [16]

Making the evidence available

The National Library of Medicine documents Varmus's advocacy for open access, including the E-Biomed proposal and his role in the Public Library of Science. Making research available allows more people to examine the methods, results and limitations behind a medical claim. Access does not make every paper easy to interpret, but it makes independent scrutiny more possible and allows knowledge to circulate beyond the institutions that produced it. [17]

A contribution beyond the laboratory

Varmus's career connects discovery with the conditions that help science advance: capable institutions, supported research communities and access to findings. His achievements sit alongside collaborators' work and the many investigations that extended those discoveries. A physician-scientist can contribute both to new knowledge and to the systems that make it available to others.

From the published Graymedy feature [14]. Sources [15-17] on page 10.

GE HealthCare SIGNA Bolt

A closer look at premium MRI workflow.

GRAYMEDY EDITORIAL / PUBLISHED 21 OCTOBER 2026

THE PRODUCT IN CONTEXT

3 TESLA
Wide-bore MRI platform

US 510(k) CLEARANCE
Announced February 2026

LOCAL AVAILABILITY
Verify the exact market and configuration. [19,20]



Image: GE HealthCare / RSNA press kit. Official manufacturer product image.

A scanner is also a workflow

SIGNA Bolt links a 3T scanner with deep-learning tools and workflow support. Its practical value depends on the whole appointment, from preparation and positioning to reconstruction and reporting. [18]

What the manufacturer offers

GE HealthCare describes a wide-bore 3T MRI platform with deep-learning reconstruction and SIGNA One workflow tools. The company announced US FDA 510(k) clearance on 19 February 2026. Its product information states that the system is not CE marked and is not available in all regions. Those are market-specific statements, not a worldwide permission to purchase or use it. [19,20]

Claims need their conditions

The product materials connect AIR Recon DL with sharper images and Sonic DL with faster acquisition, using specified comparisons. A reduction in acquisition time cannot be applied automatically to the whole appointment. Performance depends on the sequences, anatomies and configurations tested, the image-quality comparison and the functions included in the installation. [20]

The patient remains central

NIBIB explains that MRI uses magnetic fields and radiofrequency signals, without the ionising radiation used in X-ray imaging. Implant screening, noise protection and appropriate clinical preparation remain important. A premium scanner does not replace the clinical decision about whether MRI answers the patient's question. [21]

The complete imaging service

Repeat scans, staff training, service support, interoperability and running costs affect an imaging department's performance. Technical capabilities alone do not establish superiority over competing scanners. The practical standard is reliable examinations that support useful decisions, with a suitable protocol and an experienced team around the patient. [18]

From the published Graymedy feature [18]. Sources [19-21] on page 10.

The record behind the reporting

Evidence cutoff: 31 October 2026. Sources distinguish peer-reviewed research, institutional summaries, company announcements and preclinical work. Publication dates and study periods are listed separately where relevant.

[1] Sullivan et al. START-001. Nature Medicine, 23 Oct 2026. Published trial abstract. Read source

[2] NIH. Precision T-cell therapy in resistant cancers, 23 Oct 2026. Institutional account. Read source

[3] NCI. Immunotherapy to Treat Cancer. BackgroundRead source

[4] NCI. Immunotherapy Side Effects. Background.Read source

[5] NCI. How Do Clinical Trials Work? Trial-phase context.Read source

[6] argenx. FB102 phase 2 topline results, 8 Oct 2026. Sponsor announcement; full data pending. Read source

[7] NIDDK. Treatment for Celiac Disease. Current-care background. Read source

[8] NHS. Coeliac disease: treatment. Current-care backgroundRead source

[9] Academy of Nutrition and Dietetics guideline, 2023. PubMed abstract. Read source

[10] King's College London. Mapping human immune ageing, 13 Oct 2026. Institutional summary of Immunity research.Read source

[11] UCL. Immune rejuvenation industry collaboration, 8 Oct 2026. Development announcement. Read source

[12] UCL via EurekAlert. New trial aims to extend immune system lifespan, 17 Jun 2026. Trial plans. Read source

[13] Lanna et al. Sestrin-MAPK disruptors. bioRxiv, 21 May 2024. Preprint; not peer reviewed. Read source

[14] Graymedy. Dr. Harold Varmus profile, 29 Oct 2026Read source

[15] Nobel Assembly. Medicine prize press release, 1989.Read source

[16] NIH. Harold E. Varmus: historical biography. Read source

[17] NLM. Harold Varmus papers: biographical history.Read source

[18] Graymedy. SIGNA Bolt product spotlight, 21 Oct 2026.Read source

[19] GE HealthCare. Clearance announcement, 19 Feb 2026.Read source

[20] GE HealthCare. SIGNA Bolt product specifications.Read source

[21] NIBIB. Magnetic Resonance Imaging: education. Read source

PHOTOGRAPHY & PERMISSIONS

Page 01 / NCI Photo ct10qdGv1hQ

Page 02 / NCI Photo rHfsPolwIgk

Page 04 / Mae Mu Photo Emhz3miT6mo

Page 05 / NCI Photo MOj06jBit0s

Page 06 / Mobio MarketingPhoto I-6xpNpiVIc

Page 07 / NCI Photo rAJHnQz5jHc

Page 08 / Matthew SeptimusNCI via Wikimedia Commons, 2009. Public-domain photograph; published Graymedy graphic.

Page 09 / GE HealthCareRSNA press kit Official product image supplied for editorial coverage; retained Graymedy copy.

Pages 01-07, six distinct photographs, Unsplash License, free editorial and commercial reuse, including cropping. Source files retained at 3200 px width. Those context images do not depict the trials, products, investigators or patients discussed. NCI = National Cancer Institute. No endorsement implied.

UNDERSTANDING THE EVIDENCE

Early clinical activity supports further testing. A statistically significant result does not describe the size of a benefit. An observational association does not establish causation. Regulatory clearance and comparative clinical superiority are different determinations.

Publication date: Sunday, 1 November 2026. Health information is general; individual treatment decisions require clinical assessment.